BMJ Open Detection of intracranial hypertension in children using optical coherence tomography: a systematic review protocol

Sohaib R Rufai ^{1,2}, Noor ul Owase Jeelani,^{3,4} Rebecca J McLean²

To cite: Rufai SR, Jeelani NuO, McLean RJ. Detection of intracranial hypertension in children using optical coherence tomography: a systematic review protocol. *BMJ Open* 2020;**10**:e037833. doi:10.1136/bmjopen-2020-037833

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-037833>).

Received 18 February 2020
Revised 17 April 2020
Accepted 01 June 2020

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

¹Clinical and Academic Department of Ophthalmology, Great Ormond Street Hospital for Children, London, United Kingdom

²University of Leicester Ulverscroft Eye Unit, Leicester Royal Infirmary, Leicester, United Kingdom

³Craniofacial Unit, Great Ormond Street Hospital for Children, London, United Kingdom

⁴Developmental Biology & Cancer Dept, UCL GOS Institute of Child Health, London, United Kingdom

Correspondence to

Dr Rebecca J McLean;
rjm19@leicester.ac.uk

ABSTRACT

Introduction Intracranial hypertension (ICH) in children can have deleterious effects on the brain and vision. It is notoriously difficult to estimate intracranial pressure (ICP) in children and existing methods deliver suboptimal diagnostic accuracy to be used as screening tools. Optical coherence tomography (OCT) may represent a valuable, non-invasive surrogate measure of ICP, as has been demonstrated in a number of associated conditions affecting adults. More recently, OCT has been employed within the paediatric age group. However, the role of OCT in detecting ICH in children has not been rigorously assessed in a systematic review for all relevant conditions. Here, we propose a systematic review protocol to examine the role of OCT in the detection of ICH in children.

Methods and analysis Electronic searches in the Cochrane Central Register of Controlled Trials, Medline, Embase, Web of Science and PubMed will identify studies featuring OCT in detecting ICH in children. Two independent screeners will identify studies for inclusion using a screening questionnaire. The systematic search and screening will take place between 2 April 2020 and 1 June 2020, while we aim to complete data analysis by 1 September 2020. Quality assessment will be performed using the National Institutes of Health Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. The primary outcome measure is the sensitivity and specificity of OCT in detecting ICH in children. Secondary outcomes measures include conditions associated with ICH per study, direct ICP monitoring, sensitivity and specificity of other measures for ICP and OCT parameters used.

Ethics and dissemination Ethical approval is not required for the proposed systematic review as no primary data will be collected. The findings will be disseminated through presentations at scientific meetings and peer-reviewed journal publication.

PROSPERO registration number CRD42019154254.

INTRODUCTION

Intracranial hypertension

Intracranial hypertension (ICH) was first described by Quinke in 1896 and remains a subject of major importance among the medical profession.¹ ICH can pose devastating consequences if untreated, including

Strengths and limitations of this study

- The proposed study will be the first to examine the role of optical coherence tomography for all paediatric conditions associated with intracranial hypertension.
- This protocol provides transparency to the proposed systematic review methodology and reduces the possibility of duplication.
- The proposed methodology is recommended by the Cochrane Collaboration.
- A scarcity of relevant randomised controlled trials and associated high risk of bias of observational studies may be the main limitations in the evidence returned by this systematic review.
- The broad search strategy may result in a large number of titles and abstracts to screen initially.

visual impairment, neurocognitive delay, disability and death.²⁻³ Subacute conditions in children can cause insidious elevation of intracranial pressure (ICP) which may go undetected before insult to the brain and vision has already begun.²⁻⁴ Hence, early detection of ICH is crucial in enabling timely medical intervention to prevent or limit the sequelae of ICH.

ICH affects between 0.63 and 0.71 per 100 000 children.⁵⁻⁶ ICH can be broadly classified as primary (or idiopathic) and secondary. Primary ICH is characterised by elevated ICP with no identifiable cause.⁴⁻⁷ Common risk factors for primary ICH include female gender, obesity and postpubertal status, although it is known to occur in children with a lack of predilection for gender and obesity.⁴⁻⁸⁻¹⁴ Secondary ICH describes elevated ICP that is a direct result of another condition, for example, an expansive intracranial process, such as space occupying lesion or hydrocephalus, or a constricting skull pathology, such as the premature fusion of cranial sutures in craniosynostosis.²⁻⁴

Measurement of ICP

ICP measurement in children is notoriously difficult. The gold standard measure is direct intraparenchymal ICP measurement, which involves overnight admission to hospital and general anaesthesia. The risks of intraparenchymal ICP measurement include infection, haemorrhage, cerebrospinal fluid (CSF) leak and device failure.^{15 16} Furthermore, there is no universal agreement on timing, duration and frequency for accurate measurement or indeed agreement on the normal paediatric range of ICP – 11 to 15 mm Hg is widely considered normal, but Hayward *et al* argue that the upper limit could reasonably be raised to 20 mm Hg.^{17 18}

The ideal screening method for ICH should be sensitive, specific and child friendly with the ability to record objective serial measurements over time. However, existing methods fail to satisfy all of these criteria. Visual evoked potentials (VEP) assess the amplitude and latency time of the averaged encephalographic response to visual stimulus. Axonal injury secondary to ICH is associated with reduction of amplitude or prolongation of the latency time.^{2 19} However, limitations of VEP include the need for good cooperation by the child, plus high variability in normal subjects.²⁰ Fundus examination can permit direct visualisation of papilloedema or optic atrophy, both of which are associated with ICH. A study by Tuite *et al* demonstrated that fundus examination had sensitivity of 100% in detecting ICH in children aged over 8 years, but only 22% for that in younger patients, excluding it as a suitable screening method. B-scan ocular ultrasound can be helpful in acute situations for detecting severe ICH, but possesses a sensitivity of only 11% when compared with funduscopy.^{21–24} Radiological signs, such as the ‘beaten copper’ appearance of the cranium, universally demonstrate poor sensitivity for ICH.²⁵

Optical coherence tomography

The optic nerve is primarily intracranial. Thus, ICH causes optic nerve head swelling, termed papilloedema, with secondary retinal changes. These changes can be measured objectively using optical coherence tomography (OCT)—a non-invasive imaging technique that can acquire ultrahigh resolution, three-dimensional images of the back of the eye within seconds.²⁶ OCT has been used to describe the normal development of the optic nerve²⁷ and fovea^{27 28} in children. OCT has also been used in a wide range of conditions within paediatric ophthalmology, including retinopathy of prematurity,²⁹ retinoblastoma,³⁰ nystagmus,³¹ albinism,³² achromatopsia,³³ foveal hypoplasia,³⁴ optic nerve hypoplasia,³⁵ primary congenital glaucoma,³⁶ microcephaly³⁷ and others. Furthermore, OCT has been successfully used as a diagnostic tool in a variety of conditions associated with ICH, including idiopathic ICH, craniosynostosis and hydrocephalus.^{38–44}

Thus, OCT may represent an ideal screening method for ICH in children owing to its quick acquisition time and non-invasive, child-friendly nature. However, this has

not yet been rigorously assessed in a systematic review. Here, we propose to conduct the first systematic review examining the role of OCT in all conditions associated with ICH in children.

Objectives

The primary research objective of this proposed systematic review is to assess the sensitivity and specificity of OCT in detecting ICH in children.

The secondary research objectives are as follows:

- ▶ To assess which conditions associated with ICH have been successfully studied by OCT.
- ▶ To assess OCT success rate per condition per study.
- ▶ To identify surrogate measures of ICP and their associated sensitivity, specificity and success rates.
- ▶ To assess which ICP range is determined as normal per condition per study.

METHODS

This protocol has adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) checklist.⁴⁵

Eligibility criteria

The Population, Intervention, Comparison, Outcome and Study design strategy⁴⁶ has been employed to outline the eligibility criteria for this systematic review, as summarised in [table 1](#).

Types of outcome measures

The main outcome measure will be sensitivity and specificity for OCT measures in detecting ICH. OCT metrics may include one or more of the following:

- ▶ Optic nerve parameters: cup depth, cup width, cup volume, disc width and cup to disc ratio.
- ▶ Rim parameters: retinal nerve fibre layer thickness, rim area, rim volume, Bruch’s membrane opening-minimum rim width, Bruch’s membrane orientation, ganglion cell layer thickness, full peripapillary analysis.
- ▶ Retinal parameters: macular and perimacular retinal thickness, foveal pit width, depth and area, plus segmentation of all retinal layers.

The secondary outcome measures are as follows:

- ▶ Condition(s) associated with ICH per study.
- ▶ OCT success rate.
- ▶ Other surrogate estimates of ICP.
- ▶ Other OCT parameters not listed above.
- ▶ ICP range determined as normal.

Quality-of-life outcomes

Quality-of-life outcomes and patient satisfaction measured by surveys will be included where applicable.

Adverse events

The process of OCT imaging cannot directly produce adverse events as it is a safe and non-invasive imaging method that uses low-coherence light.⁴⁷ It does not involve ionising radiation.

Table 1 Eligibility criteria

PICOS strategy ⁴⁶	Inclusion criteria	Exclusion criteria
P—Population	Studies of children, defined as being aged under 18 years, diagnosed with conditions associated with ICH.	(i) Studies of adults aged 18 years old or over; (ii) Studies not pertaining to the diagnosis of ICH.
I—Intervention	Studies employing OCT to detect ICH.	Any studies that do not include OCT.
C—Comparator	Absence of a comparator will not lead to exclusion of studies, as it may be unethical to deprive one arm of the study of OCT when it may lead to a better clinical outcome in such a dangerous situation of ICH.	N/A
O—Outcome	Sensitivity and specificity of any OCT measure(s), ±surrogate measure(s), for ICH.	Studies that do not report OCT measures.
S—Study design	All level IV evidence and above, that is, systematic reviews, randomised controlled trials, cohort studies, case-control studies and case series, as defined by the Oxford Centre for Evidence-based Medicine. ⁵¹	Level 5 evidence, that is, expert opinion without critical appraisal.

ICP, intracranial pressure; N/A, Not applicable; OCT, optical coherence tomography; PICOS, Population Intervention Comparison Outcome and Study design.

Follow-up

There will be no minimum follow-up period set for study inclusion. In many cases, the decision to employ rapid intervention (ie, surgery) is made as soon as possible once ICH has been diagnosed. The stipulation of a minimum follow-up period would therefore risk losing valuable data from excluded studies.

Information sources

Record characteristics

There shall be no time restriction on records considered for this study. Unpublished records shall be considered. There shall be no language restrictions; all applicable non-English records will undergo professional translation from the University of Leicester Centre for Translation and Interpreting Studies.

Electronic searches

The following platforms shall be searched:

- ▶ Cochrane Central Register of Controlled Trials (including the Cochrane Eyes and Vision Group Trials Register).
- ▶ EMBASE Classic+Embase (1947 to present).
- ▶ Ovid MEDLINE(R) (1946 to present).
- ▶ Ovid MEDLIN In-Process and Other Non-Indexed Citations.
- ▶ PubMed (1948 to present).
- ▶ Web of Science Core Collection (1970 to present).

Searching other resources

Unpublished studies identified by experts will be considered against our inclusion criteria. References of included studies will be searched and the authors contacted by email or letter to identify further unpublished works

where applicable. If the authors do not reply within 14 days, a reminder will be sent by email or letter. If the authors do not reply to the reminder within 14 days, their study will be excluded.

Search strategy

Medical subject headings terms for ‘intracranial hypertension’ and ‘optical coherence tomography’ were entered into the above search platforms. Full details of search terms and strategy are included in online supplementary appendix 1.

Study records

Data management

EndNote V.X9 (Thomson Reuters, New York, New York, USA) reference management software will be used for data management.

Selection of studies

Two independent screeners (SRR and RJM) shall follow a three-stage screening method. The search will be conducted on 2 April 2020 and screening will be performed until 1 June 2020. Online supplementary appendix 2 outlines the screening questions and process. First, titles will be screened, followed by abstracts, followed by full papers. At each stage, studies shall be classified as ‘include’, ‘exclude’ or ‘unclear’, with those not excluded progressing to the next stage of screening. If any studies are classified as ‘unclear’ following the full paper screen, the study authors in question would be contacted by email or letter for clarification. If the authors fail to reply within 14 days, a reminder will be sent. If the authors fail to reply to the reminder within 14 days, their study will be excluded. If there is any disagreement over which papers

Table 2 Data to be extracted

Data category	Data to be extracted
Study characteristics	<ul style="list-style-type: none"> ▶ Author(s) ▶ Year ▶ Study design ▶ Study location ▶ Number of patients ▶ Mean age ▶ Age range
Primary outcome measures	<ul style="list-style-type: none"> ▶ OCT parameter(s) ▶ Sensitivity (%) ▶ Specificity (%)
Secondary outcome measures, where available	<ul style="list-style-type: none"> ▶ Condition(s) studies; ▶ OCT success rate; ▶ Other surrogate estimates of ICP; ▶ Sensitivity (%) ▶ Specificity (%) ▶ Other OCT parameters not listed above; ▶ ICP range determined as normal. ▶ Quality-of-life outcomes ▶ Adverse events

ICP, intracranial pressure; OCT, optical coherence tomography.

are selected for inclusion, the third arbitrator (NuOJ) shall make the final decision.

Data collection process

Our data extraction tool is included in online supplementary appendix 3, which is adapted from the Cochrane Collaboration.⁴⁸

Data items, outcomes and prioritisation

Table 2 outlines the data items to be extracted. Extraction of primary outcome measures will be addressed as these will be used to address the primary research objective of this systematic review.

Risk of bias in individual studies

The National Institutes of Health (NIH) Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies,⁴⁹ included in online supplementary appendix 4, shall be used to assess risk of bias in the included studies.

Data analysis

Scoping searches suggest that mainly observational studies will be returned by our search strategy with few relevant RCTs. Weighted means for outcome measures will only be calculated if multiple RCTs are identified. Otherwise, we shall perform a qualitative review summarising the available evidence. A narrative synthesis will be

conducted, examining the strengths, weaknesses, similarities and differences between included studies. Outcomes measures will be extracted and reported descriptively. Included studies will be evaluated based on the strength of the evidence. We aim to complete data analysis by 1 September 2020.

Confidence in cumulative evidence

The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach⁵⁰ will be employed to evaluate the strength of the body of evidence identified in this study, where applicable.

Patient and public involvement

Involvement of patients and the public in the development of this systematic protocol is not applicable, as no patient recruitment will take place.

ETHICS AND DISSEMINATION

Ethical approval is not required for the proposed systematic review as no primary data will be collected. The findings of this systematic review shall be disseminated through presentations at scientific meetings, as well as peer-reviewed, open-access journal publication. Data generated during this systematic review will be made available from the corresponding author on reasonable request.

DISCUSSION

To the best of our knowledge, this is the first proposed systematic review to rigorously examine the role of OCT in detecting ICH in children. We have adhered to the PRISMA-P checklist⁴⁵ when developing this protocol. Two independent screeners shall conduct the search, with a third arbitrator available if required. Quality will be assessed using the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.⁴⁹ This systematic review should help to clarify the role of OCT as a non-invasive screening method for ICH in paediatrics. The main limitations of the study may be due to the low number of relevant RCTs and higher risk of bias associated with observational studies returned by the systematic review. Publication of this protocol should provide transparency to our proposed systematic review methodology as well as reduce the possibility of duplication.

Twitter Sohaib R Rufai @OphthoReg and Noor ul Owase Jeelani @OwaseJ

Acknowledgements The authors would like to thank Irene Gottlob and Frank Proudlock of the University of Leicester Ulverscroft Eye Unit, for their support and contributions towards this systematic review protocol.

Collaborators N/A.

Contributors SRR: concept, methodology, protocol writing and final approval. NuOJ: supervision, concept, critical revision and final approval. RJM: supervision, methodology, critical revision, final approval and guarantor of review.

Funding The Medical Research Council (London, UK; grant no.: MR/N004566/1). SRR is funded by a National Institute for Health Research (NIHR) Doctoral Fellowship for this research project. This paper presents independent research funded by the

NIHR and MRC. The views expressed are those of the authors and not necessarily those of the MRC, the NHS, the NIHR or the Department of Health and Social Care.

Disclaimer The views expressed are those of the author(s) and not necessarily those of the MRC, the NHS, the NIHR or the Department of Health and Social Care.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iD

Sohaib R Rufai <http://orcid.org/0000-0001-8134-6393>

REFERENCES

- Quincke H. Ueber meningitis serosa und verwandte Zustände. *Deutsche Zeitschrift für Nervenheilkunde* 1896;9:149–68.
- Derderian C, Seaward J. Syndromic craniosynostosis. *Semin Plast Surg* 2012;26:064–75.
- Jordan CO, Aylward SC. Intracranial hypertension: a current review. *Curr Opin Pediatr* 2018;30:764–74.
- Aylward SC, Reem RE, Hypertension PI. Pediatric intracranial hypertension. *Pediatr Neurol* 2017;66:32–43.
- Matthews Y-Y, Dean F, Lim MJ, et al. Pseudotumor cerebri syndrome in childhood: incidence, clinical profile and risk factors in a national prospective population-based cohort study. *Arch Dis Child* 2017;102:715–21.
- Gillson N, Jones C, Reem RE, et al. Incidence and demographics of pediatric intracranial hypertension. *Pediatr Neurol* 2017;73:42–7.
- Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. *J Neurol Neurosurg Psychiatry* 2018;89:1088–100.
- Radhakrishnan K, Thacker AK, Bohlaga NH, et al. Epidemiology of idiopathic intracranial hypertension: a prospective and case-control study. *J Neurol Sci* 1993;116:18–28.
- Raoof N, Sharrack B, Pepper IM, et al. The incidence and prevalence of idiopathic intracranial hypertension in Sheffield, UK. *Eur J Neurol* 2011;18:1266–8.
- Radhakrishnan K, Ahlskog JE, Cross SA, et al. Idiopathic intracranial hypertension (pseudotumor cerebri). descriptive epidemiology in Rochester, Minn, 1976 to 1990. *Arch Neurol* 1993;50:78–80.
- Cinciripini GS, Donahue S, Borchert MS. Idiopathic intracranial hypertension in prepubertal pediatric patients: characteristics, treatment, and outcome. *Am J Ophthalmol* 1999;127:178–82.
- Kesler A, Fattal-Valevski A. Idiopathic intracranial hypertension in the pediatric population. *J Child Neurol* 2002;17:745–8.
- Babikian P, Corbett J, Bell W. Idiopathic intracranial hypertension in children: the Iowa experience. *J Child Neurol* 1994;9:144–9.
- Phillips PH, Repka MX, Lambert SR. Pseudotumor cerebri in children. *J Aapos* 1998;2:33–8.
- Zhang X, Medow JE, Iskandar BJ, et al. Invasive and noninvasive means of measuring intracranial pressure: a review. *Physiol Meas* 2017;38:R143–82.
- Tamburrini G, Caldarelli M, Massimi L, et al. Intracranial pressure monitoring in children with single suture and complex craniosynostosis: a review. *Childs Nerv Syst* 2005;21:913–21.
- Renier D, Sainte-Rose C, Marchac D, et al. Intracranial pressure in craniostenosis. *J Neurosurg* 1982;57:370–7.
- Hayward R, Britto J, Dunaway D, et al. Connecting raised intracranial pressure and cognitive delay in craniosynostosis: many assumptions, little evidence. *J Neurosurg Pediatr* 2016;18:242–50.
- Thompson DA, Liasis A, Hardy S, et al. Prevalence of abnormal pattern reversal visual evoked potentials in craniosynostosis. *Plast Reconstr Surg* 2006;118:184–92.
- Andersson L, Sjölund J, Nilsson J. Flash visual evoked potentials are unreliable as markers of ICP due to high variability in normal subjects. *Acta Neurochir* 2012;154:121–7.
- Dubourg J, Javouhey E, Geeraerts T, et al. Ultrasonography of optic nerve sheath diameter for detection of raised intracranial pressure: a systematic review and meta-analysis. *Intensive Care Med* 2011;37:1059–68.
- Driessen C, van Veelen M-LC, Lequin M, et al. Nocturnal ultrasound measurements of optic nerve sheath diameter correlate with intracranial pressure in children with craniosynostosis. *Plast Reconstr Surg* 2012;130:448e–51.
- Bolesch S, von Wegner F, Senft C, et al. Transcranial ultrasound to detect elevated intracranial pressure: comparison of septum pellucidum undulations and optic nerve sheath diameter. *Ultrasound Med Biol* 2015;41:1233–40.
- Driessen C, Bannink N, Lequin M, et al. Are ultrasonography measurements of optic nerve sheath diameter an alternative to funduscopy in children with syndromic craniosynostosis? *J Neurosurg Pediatr* 2011;8:329–34.
- Tuite GF, Evanson J, Chong WK, et al. The beaten copper cranium: a correlation between intracranial pressure, cranial radiographs, and computed tomographic scans in children with craniosynostosis. *Neurosurgery* 1996;39:691–8.
- Lee H, Proudlock FA, Gottlob I. Pediatric optical coherence tomography in clinical Practice-Recent progress. *Invest Ophthalmol Vis Sci* 2016;57:iovs.15-18825:OCT69.
- Patel A, Purohit R, Lee H, et al. Optic nerve head development in healthy infants and children using handheld spectral-domain optical coherence tomography. *Ophthalmology* 2016;123:2147–57.
- Lee H, Purohit R, Patel A, et al. In vivo foveal development using optical coherence tomography. *Invest Ophthalmol Vis Sci* 2015;56:4537–45.
- Anwar S, Nath M, Patel A, et al. Potential utility of foveal morphology in preterm infants measured using hand-held optical coherence tomography in retinopathy of prematurity screening. *Retina* 2019;IAE.00000000000002622.
- Soliman SE, VandenHoven C, MacKeen LD, et al. Optical coherence Tomography-Guided decisions in retinoblastoma management. *Ophthalmology* 2017;124:859–72.
- Lee H, Proudlock F, Gottlob I. Is handheld optical coherence tomography reliable in infants and young children with and without nystagmus? *Invest Ophthalmol Vis Sci* 2013;54:8152–9.
- Mohammad S, Gottlob I, Sheth V, et al. Characterization of abnormal optic nerve head morphology in albinism using optical coherence tomography. *Invest Ophthalmol Vis Sci* 2015;56:4611–8.
- Thomas MG, Kumar A, Kohl S, et al. High-Resolution in vivo imaging in achromatopsia. *Ophthalmology* 2011;118:882–7.
- Rufai SR, Thomas MG, Purohit R, et al. Can structural grading of foveal hypoplasia predict future vision in infantile nystagmus?: a longitudinal study. *Ophthalmology* 2020;127:492–500.
- Pilat A, Sibley D, McLean RJ, et al. High-Resolution imaging of the optic nerve and retina in optic nerve hypoplasia. *Ophthalmology* 2015;122:1330–9.
- Pilat AV, Proudlock FA, Shah S, et al. Assessment of the anterior segment of patients with primary congenital glaucoma using handheld optical coherence tomography. *Eye* 2019;33:1232–9.
- Papageorgiou E, Pilat A, Proudlock F, et al. Retinal and optic nerve changes in microcephaly: an optical coherence tomography study. *Neurology* 2018;91:e571–85.
- Optical Coherence Tomography Substudy Committee, NORDIC Idiopathic Intracranial Hypertension Study Group. *Papilledema outcomes from the optical coherence tomography substudy of the idiopathic intracranial hypertension treatment trial. Ophthalmology* 2015;122:1939–45.
- Scott CJ, Kardon RH, Lee AG, et al. Diagnosis and grading of papilledema in patients with raised intracranial pressure using optical coherence tomography vs clinical expert assessment using a clinical staging scale. *Arch Ophthalmol* 2010;128:705–11.
- Skau M, Yri H, Sander B, et al. Diagnostic value of optical coherence tomography for intracranial pressure in idiopathic intracranial hypertension. *Graefes Arch Clin Exp Ophthalmol* 2013;251:567–74.
- Anand A, Pass A, Urfy MZ, et al. Optical coherence tomography of the optic nerve head detects acute changes in intracranial pressure. *J Clin Neurosci* 2016;29:73–6.
- Patel MD, Malhotra K, Shirazi Z, et al. Methods for quantifying optic disc volume and peripapillary deflection volume using radial optical coherence tomography scans and association with intracranial pressure. *Front Neurol* 2019;10:798.
- Swanson JW, Aleman TS, Xu W, et al. Evaluation of optical coherence tomography to detect elevated intracranial pressure in children. *JAMA Ophthalmol* 2017;135:320–8.
- Swanson JW, Xu W, Ying G-S, et al. Intracranial pressure patterns in children with craniosynostosis utilizing optical coherence tomography. *Childs Nerv Syst* 2020;36:535–44.

- 45 Shamseer L, Moher D, Clarke M, *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647.
- 46 Higgins JP, Green S. *Defining the review question and developing criteria for including studies, in Cochrane handbook for systematic reviews of interventions.* Wiley Online Library, 2008: 1–83.
- 47 Fujimoto JG, Bouma B, Tearney GJ, *et al.* New technology for high-speed and high-resolution optical coherence tomography. *Ann N Y Acad Sci* 1998;838:95–107.
- 48 Cochrane. Data extraction forms, 2019. Available: <https://dplp.cochrane.org/data-extraction-forms> [Accessed 24 Oct 2019].
- 49 NIH. *Study Quality Assessment Tools: Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.* Available: <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools> [Accessed 24 Oct 2019].
- 50 Iorio A, Spencer FA, Falavigna M, *et al.* Use of grade for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. *BMJ* 2015;350:h870.
- 51 CEBM. *Oxford Centre for Evidence-based Medicine – Levels of Evidence* (March 2009). Available: <https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/> [Accessed 24 Oct 2019].